Amsterdam-based healthtech startup Clear.bio has secured €1.7M in fresh funding to scale its digital diabetes remission program.
The round saw participation from Horizon Flevoland, Future Food Fund, Invest International’s Dutch Trade & Investment Fund, and several angel investors.
The company will use the funds to accelerate rollout in the Netherlands while preparing for reimbursement from health insurers in France and Germany.
Tackling type-2 diabetes with data-driven care
Founded in 2019 by Madelon Bracke and Piet Hein van Dam, Clear.bio helps people manage type-2 diabetes through a fully personalised diet plan based on individual glucose data. Users receive real-time advice directly from the app — with features like Smart Swap (suggesting healthier food alternatives) and Smart Signal (alerts when glucose spikes occur).
The approach aims to go beyond medication, giving patients an accessible way to put type-2 diabetes into remission. In June 2025, Clear.bio became officially registered as a Class I medical device under European MDR regulation, ensuring compliance with the highest medical standards.xample, Personio reduced deal creation time by 60%, while Clari expanded market coverage by over 20%.
Advertisement
Scaling impact across Europe
CEO Piet Hein van Dam said:
“There are 70 million patients in Europe, all of whom deserve a chance to get rid of this disease without medication. This investment allows us to empower more individuals to take charge of their health and expand our proven solution internationally.”
With demand for affordable, scalable solutions to diabetes rising, Clear.bio plans to strengthen partnerships with hospitals, insurers, and pharmaceutical players while ramping up adoption across Europe.
